Hirsutism future or investigational therapies: Difference between revisions
| Line 8: | Line 8: | ||
==Future or Investigational Therapies== | ==Future or Investigational Therapies== | ||
Fluridil (2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl) phenyl]-3-(2,2,2-trifluoroacetylamino)ropanamide) is a new topical antiandrogen agent and has been developed for hyperandrogenic skin syndromes. | |||
A clinical study has shown that a 2% fluridil gel is a safe and effective treatment method of hirsutism and also has no effect on libido or sexual function but Fluridil is not available yet.<ref name="pmid12174057">{{cite journal |vauthors=Sovak M, Seligson AL, Kucerova R, Bienova M, Hajduch M, Bucek M |title=Fluridil, a rationally designed topical agent for androgenetic alopecia: first clinical experience |journal=Dermatol Surg |volume=28 |issue=8 |pages=678–85 |year=2002 |pmid=12174057 |doi= |url=}}</ref> | |||
==References== | ==References== | ||
Revision as of 17:20, 15 September 2017
|
Hirsutism Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Medical Therapy |
|
Case Studies |
|
Hirsutism future or investigational therapies On the Web |
|
Directions to Hospitals Treating Hirsutism future or investigational therapies |
|
Risk calculators and risk factors for Hirsutism future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief:
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Overview
Future or Investigational Therapies
Fluridil (2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl) phenyl]-3-(2,2,2-trifluoroacetylamino)ropanamide) is a new topical antiandrogen agent and has been developed for hyperandrogenic skin syndromes.
A clinical study has shown that a 2% fluridil gel is a safe and effective treatment method of hirsutism and also has no effect on libido or sexual function but Fluridil is not available yet.[1]